Inflammation News and Research

RSS

Omega-3 fish oils: Natural health solution for the heart

Did you know that over the average life span, a heart beats 2 to 3 billion times? As one of the hardest working muscles pumping oxygen and essential nutrients throughout your body an average of 100,000 times a day, the heart needs a lot of help to stay working fit.

25 Feb 2011

FN-EDA protein can reduce damage after heart attack

Scientists have identified a protein that plays a key role in debilitating changes that occur in the heart after a heart attack, according to research reported in Circulation Research: Journal of the American Heart Association.

25 Feb 2011

Positive results from Vertex VX-770 Phase 3 STRIVE study in patients with CF

Vertex Pharmaceuticals Incorporated today announced positive results from the Phase 3 STRIVE study of VX-770, an oral medicine in development that targets the defective protein that causes cystic fibrosis.

24 Feb 2011

FDA allows marketing of Ridascreen Norovirus 3rd Generation EIA assay in the US

The U.S. Food and Drug Administration allowed marketing of the first test for the preliminary identification of norovirus.

24 Feb 2011

ProtoKinetix demonstrates ability of AAGP molecules against inflammatory diseases

ProtoKinetix (OTCBB: PKTX) (www.protokinetix.com ), a biotechnology company that has developed and patented a family of synthetic anti-aging glycopeptides (AAGP™) for medicine, biotechnology and cosmetic industries stated that it has repeatedly demonstrated the ability of their AAGP™ molecule to protect against the attacks of the most hostile inflammation causing agents known.

24 Feb 2011

FDA clears Entellus Medical's new FinESS Endoscope

Entellus Medical, a Minnesota-based medical technology company, announced today that the U.S. Food and Drug Administration cleared the company's new FinESS Endoscope.

23 Feb 2011

USPTO issues patent to Synergy's SP-333 for treatment of IBD

Synergy Pharmaceuticals, Inc., a developer of new drugs to treat gastrointestinal disorders and diseases, announced today that on February 1, 2011 the U.S. Patent and Trademark Office issued U.S. Patent No. 7,879,802, covering Synergy's novel drug candidate SP-333 to treat inflammatory bowel disease.

23 Feb 2011

American Journal of Clinical Oncology publishes CTI's OPAXIO phase II results against esophageal cancer

Cell Therapeutics, Inc. announced today that updated phase II study results of OPAXIO in patients with advanced esophageal cancer conducted by the Brown University Oncology Group were published in the February 3, 2011 issue of the American Journal of Clinical Oncology, Dipetrillo, et al., which demonstrate that 38% of the patients receiving OPAXIO in combination with cisplatin and concurrent radiation achieved a pathologic or endoscopic complete response.

23 Feb 2011

Positive results from Harbor BioSciences' Triolex initial preclinical study for treatment of PD

Harbor BioSciences, Inc., which is investigating the use the company's proprietary compound Triolex as a treatment for Parkinson's disease with funding from The Michael J. Fox Foundation, announced positive results in initial preclinical studies.

23 Feb 2011

Gilead Sciences signs definitive agreement to acquire Calistoga for $375 million

Gilead Sciences, Inc. and Calistoga Pharmaceuticals, Inc., a privately-held biotechnology company focused on the development of medicines to treat cancer and inflammatory diseases, today announced the signing of a definitive agreement pursuant to which Gilead will acquire Calistoga for $375 million.

22 Feb 2011

Why are Chlamydia and HPV major public health problems?

Chlamydia trachomatis is a bacterium that is one of the most common sexually transmitted infections in Europe. Rates in sexually active young people are commonly between 5% and 10%. The number of diagnosed cases is increasing in many European countries, in part due to increased testing and the use of more sensitive tests.

22 Feb 2011

Experimental vaccine appears to protect against pneumonia

Researchers at Albert Einstein College of Medicine of Yeshiva University have developed an experimental vaccine that appears to protect against an increasingly common and particularly deadly form of pneumococcal pneumonia. Details of the new vaccine, which was tested in an animal model, are reported in a paper published today in the Journal of Infectious Diseases.

22 Feb 2011

Research: Blood and hormone level in saliva can reveal burnout symptoms

Your blood and the level of a hormone in your spit could reveal if you're on the point of burnout, according to research undertaken by Dr. Sonia Lupien and Robert-Paul Juster of the Centre for Studies on Human Stress of Louis-H. Lafontaine Hospital and the University of Montreal.

22 Feb 2011

Studies identify protein that drives inflammation in pancreatic, breast tumors

Separate studies published online on February 21 in the Journal of Experimental Medicine (www.jem.org) identify a protein that drives tumor-promoting inflammation in pancreatic and breast tumors.

21 Feb 2011

Slime of starfish may hold a clue for treating inflammatory diseases

Starfish have arms, spines and a mouth on the underside of its body. But what scientists are finding really interesting is the sticky goo which is secreted when the Starfish feels threatened. The slime contains properties which may prove invaluable in treating certain kinds of inflammatory illnesses.

20 Feb 2011

Treating depression: A vital step in cancer recovery

With all of the stresses of today’s modern world, depression is unfortunately becoming a common household word for many people in this country and abroad. During the cold winter months, many also struggle with seasonal depression or “winter blues,” known as Seasonal Affective Disorder (SAD). Depression can be caused by any number of factors, such as chronic stress, inactivity, hormone or neurotransmitter imbalances, nutritional deficiencies, medication side effects, chronic inflammation, or lack of adequate sunshine exposure, among others.

20 Feb 2011

Phase I/II safety, efficacy data for Bellicum's BPX-101 presented at 2011 Genitourinary Cancers Symposium

Bellicum Pharmaceuticals, Inc. today announced the presentation of Phase I/II safety and efficacy data for BPX-101, a novel drug-activated dendritic cell vaccine for metastatic castrate resistant prostate cancer (mCRPC), in three separate posters at the 2011 Genitourinary Cancers Symposium held in Orlando, Florida on February 17 – 19, 2011.

19 Feb 2011

New, simple device to detect lung pathogens causing pneumonia

Researchers from the Georgia Institute of Technology have created a new sampling device that could prevent thousands of people worldwide from dying of pneumonia each year.

19 Feb 2011

New tuberculosis vaccine provides better protection

Nele Festjens and Nico Callewaert of VIB and Ghent University have improved the efficacy of the vaccine for tuberculosis. The new vaccine affords - as already proven in mice - better protection against the disease. The development of a new tuberculosis vaccine is a priority in the fight against the disease which claims the lives of 1.7 million people each year. The current vaccine provides only partial protection.

19 Feb 2011

Doctor explores link between lack of oxygen and inflammation in patients undergoing surgery

When the body is deprived of oxygen during a major surgery, the kidneys, heart muscles or lungs can be injured as a result. The problem is that lack of oxygen can lead to inflammation.

19 Feb 2011